Competitors of Laurus Labs Ltd in the Pharmaceuticals Sector
| Stock Name | Market Cap | Current Price | High / Low | Stock P/E | Book Value | Dividend Yield | ROCE | ROE | Face Value |
|---|---|---|---|---|---|---|---|---|---|
| Gujarat Themis Biosyn Ltd | 3,399 Cr. | 312 | 390/108 | 64.5 | 20.5 | 0.21 % | 45.0 % | 33.8 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 58.6 Cr. | 79.0 | 94.9/25.8 | 22.5 | 11.9 | 0.00 % | 9.72 % | 3.44 % | 10.0 |
| Gujarat Inject (Kerala) Ltd | 28.0 Cr. | 19.1 | 19.5/8.35 | 36.3 | 6.64 | 0.00 % | 4.06 % | 3.33 % | 10.0 |
| Godavari Drugs Ltd | 86.2 Cr. | 114 | 155/87.0 | 12.9 | 55.4 | 0.00 % | 12.7 % | 15.5 % | 10.0 |
| Glenmark Life Sciences Ltd | 12,800 Cr. | 1,046 | 1,335/620 | 30.2 | 207 | 2.15 % | 28.1 % | 21.1 % | 2.00 |
| Gennex Laboratories Ltd | 437 Cr. | 19.2 | 29.0/13.2 | 25.3 | 7.68 | 0.00 % | 14.4 % | 10.4 % | 1.00 |
| Ganga Pharmaceuticals Ltd | 7.25 Cr. | 15.0 | 28.5/13.1 | 145 | 13.4 | 0.00 % | 3.19 % | 0.84 % | 10.0 |
| Fredun Pharmaceuticals Ltd | 317 Cr. | 674 | 1,054/650 | 17.9 | 278 | 0.10 % | 17.6 % | 15.0 % | 10.0 |
| Fervent Synergies Ltd | 52.0 Cr. | 17.3 | 27.8/14.6 | 11.8 | 0.00 % | 34.8 % | 34.9 % | 10.0 | |
| Fermenta Biotech Ltd | 960 Cr. | 326 | 355/145 | 117 | 98.6 | 0.38 % | 3.20 % | 5.59 % | 5.00 |
| Fabino Enterprises Ltd | 5.88 Cr. | 28.0 | 43.8/23.6 | 118 | 20.0 | 0.00 % | 1.68 % | 1.21 % | 10.0 |
| Evoq Remedies Ltd | 18.2 Cr. | 7.31 | 19.4/7.21 | 40.4 | 18.6 | 0.00 % | 1.91 % | 1.80 % | 10.0 |
| Everest Organics Ltd | 108 Cr. | 136 | 184/110 | 50.6 | 0.00 % | 6.03 % | 0.30 % | 10.0 | |
| Murae Organisor Ltd | 128 Cr. | 1.84 | 3.10/0.98 | 173 | 3.80 | 0.00 % | 0.79 % | 0.13 % | 2.00 |
| Dipna Pharmachem Ltd | 16.5 Cr. | 6.87 | 14.5/6.40 | 15.2 | 15.6 | 0.00 % | 7.05 % | 3.52 % | 10.0 |
| Decipher Labs Ltd | 15.2 Cr. | 15.1 | 25.8/14.4 | 18.4 | 21.3 | 0.00 % | 3.09 % | 6.75 % | 10.0 |
| Coral Laboratories Ltd | 278 Cr. | 780 | 999/345 | 12.0 | 570 | 0.26 % | 12.6 % | 9.58 % | 10.0 |
| Concord Drugs Ltd | 36.0 Cr. | 36.0 | 61.5/30.6 | 33.9 | 0.00 % | 4.50 % | 1.29 % | 10.0 | |
| Colinz Laboratories Ltd | 25.2 Cr. | 55.0 | 84.4/36.0 | 45.7 | 20.5 | 0.00 % | 7.70 % | 5.73 % | 10.0 |
| Cian Healthcare Ltd | 11.8 Cr. | 4.72 | 26.5/4.12 | 47.2 | 23.1 | 0.00 % | 5.22 % | 0.43 % | 10.0 |
| Chemo Pharma Laboratories Ltd | 12.3 Cr. | 82.1 | 94.7/40.4 | 9.86 | 91.1 | 0.00 % | 13.3 % | 9.67 % | 10.0 |
| Checkpoint Trends Ltd | 7.11 Cr. | 13.0 | 17.4/4.09 | 0.93 | 0.00 % | 3.36 % | 5.77 % | 10.0 | |
| Chandra Bhagat Pharma Ltd | 52.1 Cr. | 69.0 | 160/63.0 | 33.0 | 39.4 | 0.00 % | 7.95 % | 5.42 % | 10.0 |
| Brawn Biotech Ltd | 6.23 Cr. | 20.8 | 27.8/14.6 | 14.1 | 0.00 % | 25.9 % | 21.8 % | 10.0 | |
| Bharat Immunological & Biological Corporation Ltd | 102 Cr. | 23.6 | 43.9/22.2 | 18.2 | 0.00 % | 9.27 % | 17.7 % | 10.0 | |
| Beryl Drugs Ltd | 16.6 Cr. | 32.8 | 46.0/20.2 | 48.8 | 18.3 | 0.00 % | 11.6 % | 8.95 % | 10.0 |
| BDH Industries Ltd | 198 Cr. | 344 | 408/175 | 20.4 | 110 | 1.31 % | 20.6 % | 16.9 % | 10.0 |
| Bacil Pharma Ltd | 25.6 Cr. | 43.4 | 50.0/4.68 | 65.6 | 2.87 | 0.00 % | 13.1 % | 13.8 % | 10.0 |
| Aurobindo Pharma Ltd | 71,690 Cr. | 1,224 | 1,593/958 | 19.7 | 527 | 0.37 % | 14.1 % | 11.5 % | 1.00 |
| Auro Laboratories Ltd | 124 Cr. | 200 | 307/112 | 20.2 | 69.6 | 0.00 % | 20.4 % | 20.5 % | 10.0 |
| Anuh Pharma Ltd | 977 Cr. | 195 | 265/140 | 16.6 | 60.5 | 1.28 % | 25.6 % | 19.5 % | 5.00 |
| ANG Lifesciences India Ltd | 60.1 Cr. | 46.0 | 86.1/43.5 | 56.2 | 0.00 % | 1.78 % | 8.72 % | 10.0 | |
| Ami Organics Ltd | 8,524 Cr. | 2,081 | 2,185/1,004 | 91.3 | 294 | 0.14 % | 16.0 % | 9.37 % | 10.0 |
| Amerise Biosciences Ltd | 6.34 Cr. | 0.96 | 1.20/0.55 | 0.80 | 0.00 % | 2.73 % | 2.75 % | 1.00 | |
| Ambalal Sarabhai Enterprises Ltd | 422 Cr. | 55.1 | 77.7/37.5 | 31.7 | 18.3 | 0.00 % | 7.08 % | 4.22 % | 10.0 |
| Adline Chem Lab Ltd | 14.6 Cr. | 25.0 | 29.0/11.9 | 2.70 | 0.00 % | % | % | 10.0 | |
| Achyut Healthcare Ltd | 114 Cr. | 68.0 | 82.5/40.2 | 173 | 18.5 | 0.00 % | 3.27 % | 2.52 % | 10.0 |
| Abbott India Ltd | 58,836 Cr. | 27,718 | 30,521/21,983 | 45.8 | 1,657 | 1.48 % | 46.0 % | 34.9 % | 10.0 |
| Aarti Pharmalabs Ltd | 5,913 Cr. | 653 | 722/381 | 25.9 | 205 | 0.46 % | 16.6 % | 13.1 % | 5.00 |
| Aarey Drugs & Pharmaceuticals Ltd | 156 Cr. | 56.3 | 75.8/37.0 | 22.6 | 46.6 | 0.00 % | 6.18 % | 3.81 % | 10.0 |
| Zota Health Care Ltd | 1,547 Cr. | 564 | 725/400 | 58.0 | 0.18 % | 7.32 % | 16.8 % | 10.0 | |
| Wockhardt Ltd | 20,080 Cr. | 1,233 | 1,335/323 | 221 | 0.00 % | 0.83 % | 12.1 % | 5.00 | |
| Wanbury Ltd | 734 Cr. | 221 | 291/98.4 | 26.6 | 11.8 | 0.00 % | 62.5 % | % | 10.0 |
| Vivimed Labs Ltd | 41.0 Cr. | 4.95 | / | 0.66 | 0.00 % | 11.0 % | 268 % | 2.00 | |
| Venus Remedies Ltd | 388 Cr. | 292 | 430/280 | 17.6 | 370 | 0.00 % | 8.57 % | 5.94 % | 10.0 |
| Unichem Laboratories Ltd | 6,040 Cr. | 858 | 950/401 | 121 | 341 | 0.00 % | 0.39 % | 1.17 % | 2.00 |
| TTK Healthcare Ltd | 2,119 Cr. | 1,497 | 1,923/1,232 | 32.8 | 735 | 0.67 % | 8.67 % | 6.43 % | 10.0 |
| Torrent Pharmaceuticals Ltd | 1,07,094 Cr. | 3,167 | 3,591/2,025 | 61.5 | 222 | 0.88 % | 23.2 % | 24.2 % | 5.00 |
| Themis Medicare Ltd | 2,665 Cr. | 289 | 317/154 | 50.3 | 44.8 | 0.17 % | 13.5 % | 11.8 % | 1.00 |
| Syncom Formulations (India) Ltd | 1,838 Cr. | 19.5 | 27.9/10.5 | 57.8 | 3.32 | 0.00 % | 10.2 % | 8.51 % | 1.00 |
| Suven Pharmaceuticals Ltd | 32,922 Cr. | 1,295 | 1,359/585 | 136 | 77.7 | 0.00 % | 18.8 % | 14.1 % | 1.00 |
| Suven Life Sciences Ltd | 2,560 Cr. | 117 | 169/74.5 | 8.84 | 0.00 % | 36.4 % | 36.3 % | 1.00 | |
| Sun Pharmaceuticals Industries Ltd | 4,31,322 Cr. | 1,795 | 1,960/1,184 | 38.5 | 288 | 0.75 % | 17.3 % | 16.7 % | 1.00 |
| Solara Active Pharma Sciences Ltd | 3,455 Cr. | 799 | 851/292 | 302 | 0.00 % | 8.67 % | 33.5 % | 10.0 | |
| SMS Pharmaceuticals Ltd | 2,038 Cr. | 241 | 398/113 | 34.7 | 70.6 | 0.17 % | 11.4 % | 9.53 % | 1.00 |
| SMS Lifesciences India Ltd | 315 Cr. | 1,008 | 1,750/487 | 15.5 | 621 | 0.15 % | 6.89 % | 3.66 % | 10.0 |
| Shilpa Medicare Ltd | 8,928 Cr. | 913 | 960/313 | 155 | 238 | 0.00 % | 5.25 % | 1.71 % | 1.00 |
| Sequent Scientific Ltd | 5,057 Cr. | 202 | 241/91.8 | 238 | 27.2 | 0.00 % | 0.44 % | 3.09 % | 2.00 |
| Sanofi India Ltd | 13,932 Cr. | 6,054 | 7,600/4,606 | 33.0 | 298 | 2.76 % | 71.1 % | 51.5 % | 10.0 |
| RPG Life Sciences Ltd | 3,290 Cr. | 1,992 | 2,977/1,290 | 37.8 | 229 | 0.80 % | 34.6 % | 25.5 % | 8.00 |
| Procter & Gamble Health Ltd | 8,450 Cr. | 5,095 | 5,836/4,637 | 37.3 | 324 | 1.18 % | 45.0 % | 33.5 % | 10.0 |
| Pharmaids Pharmaceuticals Ltd | 256 Cr. | 72.6 | 87.5/31.9 | 19.0 | 0.00 % | 27.6 % | 16.8 % | 10.0 | |
| Pfizer Ltd | 23,916 Cr. | 5,226 | 6,453/3,950 | 39.1 | 820 | 0.67 % | 22.0 % | 16.1 % | 10.0 |
| Par Drugs & Chemicals Ltd | 362 Cr. | 294 | 325/190 | 19.8 | 78.6 | 0.00 % | 25.0 % | 18.5 % | 10.0 |
| Panacea Biotec Ltd | 2,507 Cr. | 410 | 420/112 | 136 | 0.00 % | 3.57 % | 3.17 % | 1.00 | |
| Ortin Laboratories Ltd | 16.4 Cr. | 20.1 | 26.4/16.2 | 3.47 | 0.00 % | 60.2 % | 118 % | 10.0 | |
| Orchid Pharma Ltd | 7,420 Cr. | 1,458 | 1,592/557 | 62.4 | 241 | 0.00 % | 9.37 % | 9.94 % | 10.0 |
| Neuland Laboratories Ltd | 19,090 Cr. | 14,905 | 16,561/4,926 | 72.3 | 1,087 | 0.09 % | 33.3 % | 26.4 % | 10.0 |
| Nectar Lifescience Ltd | 755 Cr. | 33.6 | 56.5/26.2 | 70.4 | 48.1 | 0.00 % | 5.97 % | 0.46 % | 1.00 |
| Natco Pharma Ltd | 24,320 Cr. | 1,358 | 1,639/752 | 12.5 | 399 | 0.70 % | 30.1 % | 25.9 % | 2.00 |
| Morepen Laboratories Ltd | 4,052 Cr. | 73.9 | 101/38.6 | 30.9 | 20.3 | 0.00 % | 16.8 % | 12.0 % | 2.00 |
| Marksans Pharma Ltd | 13,994 Cr. | 309 | 329/126 | 40.4 | 50.3 | 0.19 % | 20.6 % | 16.5 % | 1.00 |
| Mangalam Drugs and Organics Ltd | 165 Cr. | 105 | 145/85.2 | 17.5 | 93.2 | 0.00 % | 1.19 % | 6.12 % | 10.0 |
| Lyka Labs Ltd | 512 Cr. | 143 | 173/97.9 | 162 | 27.7 | 0.00 % | 3.95 % | 6.61 % | 10.0 |
| Lupin Ltd | 94,480 Cr. | 2,071 | 2,312/1,200 | 36.0 | 343 | 0.39 % | 15.7 % | 14.1 % | 2.00 |
| Lincoln Pharmaceuticals Ltd | 1,237 Cr. | 618 | 814/498 | 12.8 | 319 | 0.29 % | 22.3 % | 16.8 % | 10.0 |
| Laurus Labs Ltd | 27,643 Cr. | 513 | 518/359 | 118 | 79.2 | 0.16 % | 7.50 % | 5.43 % | 2.00 |
| Kwality Pharmaceuticals Ltd | 895 Cr. | 863 | 961/356 | 26.0 | 234 | 0.00 % | 15.9 % | 13.7 % | 10.0 |
| Krebs Biochemicals & Industries Ltd | 177 Cr. | 82.3 | 122/60.0 | 60.4 | 0.00 % | 19.0 % | % | 10.0 | |
| Kopran Ltd | 1,058 Cr. | 220 | 370/198 | 20.0 | 103 | 1.37 % | 13.8 % | 11.0 % | 10.0 |
| Kilitch Drugs (India) Ltd | 495 Cr. | 310 | 470/298 | 35.2 | 118 | 0.00 % | 12.8 % | 7.83 % | 10.0 |
| Jubilant Pharmova Ltd | 18,128 Cr. | 1,138 | 1,310/409 | 63.7 | 373 | 0.44 % | 6.74 % | 0.76 % | 1.00 |
| J B Chemicals & Pharmaceuticals Ltd | 26,873 Cr. | 1,743 | 2,030/1,371 | 44.0 | 207 | 0.70 % | 24.6 % | 20.0 % | 1.00 |
| Jagsonpal Pharmaceuticals Ltd | 1,694 Cr. | 638 | 655/270 | 63.3 | 74.4 | 0.78 % | 17.0 % | 13.0 % | 5.00 |
| Ipca Laboratories Ltd | 40,382 Cr. | 1,591 | 1,709/1,041 | 64.8 | 264 | 0.25 % | 12.8 % | 9.35 % | 1.00 |
| IOL Chemicals & Pharmaceuticals Ltd | 2,047 Cr. | 348 | 538/331 | 20.4 | 283 | 1.44 % | 12.3 % | 8.68 % | 10.0 |
| Indoco Remedies Ltd | 2,950 Cr. | 320 | 417/286 | 132 | 118 | 0.47 % | 10.4 % | 8.33 % | 2.00 |
| Glenmark Pharmaceuticals Ltd | 41,744 Cr. | 1,478 | 1,831/764 | 299 | 0.17 % | 12.3 % | 50.9 % | 1.00 | |
| Glaxosmithkline Pharmaceuticals Ltd | 40,831 Cr. | 2,412 | 3,088/1,616 | 50.9 | 98.7 | 1.33 % | 51.3 % | 37.3 % | 10.0 |
| Dr Reddys Laboratories Ltd | 1,01,400 Cr. | 1,214 | 1,421/1,074 | 19.0 | 369 | 0.66 % | 26.5 % | 21.4 % | 1.00 |
| Dishman Carbogen Amcis Ltd | 3,588 Cr. | 228 | 283/133 | 366 | 0.00 % | 0.02 % | 2.64 % | 2.00 | |
| Cipla Ltd | 1,20,037 Cr. | 1,486 | 1,702/1,178 | 26.1 | 351 | 0.87 % | 22.8 % | 16.8 % | 2.00 |
| Caplin Point Laboratories Ltd | 14,921 Cr. | 1,964 | 2,177/1,178 | 30.2 | 334 | 0.25 % | 26.5 % | 24.2 % | 2.00 |
| Brooks Laboratories Ltd | 367 Cr. | 140 | 186/72.5 | 22.6 | 0.00 % | 24.7 % | 28.1 % | 10.0 | |
| Bliss GVS Pharma Ltd | 1,386 Cr. | 132 | 150/92.2 | 15.7 | 96.0 | 0.38 % | 14.4 % | 10.2 % | 1.00 |
| Biofil Chemicals & Pharmaceuticals Ltd | 96.3 Cr. | 59.2 | 92.0/42.6 | 182 | 11.3 | 0.00 % | 4.94 % | 4.00 % | 10.0 |
| Biocon Ltd | 39,800 Cr. | 332 | 396/231 | 27.6 | 175 | 0.15 % | 5.96 % | 5.25 % | 5.00 |
| Beta Drugs Ltd | 2,004 Cr. | 2,085 | 2,326/1,060 | 48.9 | 188 | 0.00 % | 32.8 % | 26.0 % | 10.0 |
| Bal Pharma Ltd | 218 Cr. | 137 | 158/89.0 | 28.6 | 43.2 | 0.87 % | 12.1 % | 11.1 % | 10.0 |
| Bafna Pharmaceuticals Ltd | 189 Cr. | 80.0 | 113/73.2 | 246 | 35.0 | 0.00 % | 9.48 % | 9.44 % | 10.0 |
| Astrazeneca Pharma India Ltd | 15,800 Cr. | 6,320 | 8,140/4,050 | 123 | 272 | 0.38 % | 31.1 % | 22.9 % | 2.00 |
| Amrutanjan Health Care Ltd | 2,023 Cr. | 700 | 863/556 | 42.6 | 103 | 0.66 % | 21.3 % | 15.5 % | 1.00 |
| Alpa Laboratories Ltd | 233 Cr. | 111 | 145/69.9 | 11.2 | 83.0 | 0.00 % | 13.7 % | 11.2 % | 10.0 |
| Alkem Laboratories Ltd | 66,778 Cr. | 5,583 | 6,440/4,407 | 30.7 | 961 | 0.72 % | 19.7 % | 19.6 % | 2.00 |
| Alembic Pharmaceuticals Ltd | 20,479 Cr. | 1,042 | 1,304/710 | 32.2 | 249 | 1.06 % | 13.1 % | 13.3 % | 2.00 |
| Albert David Ltd | 725 Cr. | 1,269 | 1,754/911 | 10.6 | 724 | 0.91 % | 27.8 % | 21.7 % | 10.0 |
| Ajanta Pharma Ltd | 36,975 Cr. | 2,960 | 3,486/1,850 | 42.3 | 294 | 1.22 % | 31.6 % | 23.2 % | 2.00 |
| Advanced Enzyme Technologies Ltd | 4,097 Cr. | 366 | 571/322 | 27.9 | 120 | 1.39 % | 15.2 % | 11.2 % | 2.00 |
| Aarti Drugs Limited | 4,130 Cr. | 449 | 635/430 | 33.0 | 126 | 0.22 % | 13.7 % | 12.4 % | 10.0 |
| Industry Average | 19,451.65 Cr | 1,190.01 | 55.13 | 184.88 | 0.32% | 16.40% | 16.92% | 6.61 |
About the Author
Getaka
Getaka, CFA, a financial analyst with 15 years of experience in the industry. Getaka holds an MBA degree and the Chartered Financial Analyst designation, demonstrating his profound understanding of financial analysis and investment management. Throughout his career, he has conducted numerous financial analyses and due diligence processes for companies in the industry, and has a strong track record of identifying key trends and opportunities. He leverages his expertise to deliver a thorough financial analysis of a company, encompassing its financial performance, key ratios, future prospects, and risks. Getaka is committed to providing accurate, reliable, and trustworthy information to help readers make informed decisions about their finances and investments.